• ​Operating revenue in the first quarter of 2025 was 154.9 million euros, a 2% increase on the first quarter of 2024, mainly due to the performance of the specialty pharmaceutical business, which increased 18% to 119.1 million euros, compared to 101.1 million euros in the first quarter of 2024.
• Positive evolution of Okedi® (Risperidone ISM®), which had total sales of 12.6 million euros in the first quarter of 2025. Okedi® sales increased 133% in the first quarter of 2025 compared to the first quarter of 2024 and 48% compared to the fourth quarter of 2024.
• Sales of the heparin franchise (low-molecular-weight heparins (LMWH) and other heparins) increased by 24% to 69.6 million euros in the first quarter of 2025, mostly due to a greater concentration of orders from partners in the first quarter of the year. Bemiparin was the main contributor to the growth of the division, with sales rising 38% to 27.1 million euros due to stronger international sales in the quarter. In addition, enoxaparin sales also increased by 17% to 40.6 million euros in the first quarter of 2025 compared to the first quarter of 2024.
• Good performance of Neparvis®, sales of which increased by 11% in the first quarter of 2025 compared to the first quarter of 2024, rising to 13.6 million euros.
• Gross margin was 58.5% in the first quarter of 2025, an increase of 1.8 percentage points on the first quarter of 2024. This increase was mainly due to: (i) the increased contribution of Okedi® sales, which added high margins; and (ii) the decrease in LMWH raw material prices, which had a positive impact on gross margin.
• EBITDA increased 17% to 30.3 million euros in the first quarter of 2025 compared to 25.9 million euros in the same period of 2024. This positive result reflects a 2.4 percentage point increase in the EBITDA margin, which was up from 17.1% in the first quarter of 2024 to 19.6% in the same period of 2025.
• Net profit increased 21% to 18.1 million euros in the first quarter of 2025.

OUTLOOK

For 2025, ROVI expects its operating revenue to decrease by a mid-single-digit percentage in comparison with 2024. Notwithstanding, this guidance is calculated using certain factors that could be relevant to the estimates and that are difficult to specify at the present time. They include, among others, the following:

First, as of today’s date, the Company is unable to forecast how the demand and production might evolve for the vaccination campaigns that will take place in 2025.
Second, it is hoped that the expansion of the compounding, aseptic filling, inspection, labelling and packaging capacities at the ROVI facilities in Madrid and the current high market demand for contract manufacturing services (CDMO) will favour obtaining new business, with the resulting sales impact. This would have to be considered but is impossible to estimate at this time.